3 terminated. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
| Phase 1 | 2 | Terminated 2 |
Follow Plicamycin: new trials by email Literature Review of Plicamycin trials Research Report on Plicamycin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases Mithramycin - Esophageal Neoplasms, Lung Neoplasms | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2019-08-08 | 2022-04-05 |
| Mithramycin for Lung, Esophagus, and Other Chest Cancers Mithramycin - Lung Cancer, Esophageal Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 16 | 2012-09-06 | 2019-12-30 |
| Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma Mithramycin - Ewing Sarcoma, Sarcoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 8 | 2012-05-10 | 2018-03-02 |
Esophageal Neoplasms (2) · Lung Neoplasms (2) · Mesothelioma (2) · Sarcoma (2) · Bone Neoplasms (1) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Kidney Neoplasms (1) · Neoplasms, Germ Cell and Embryonal (1) · Sarcoma, Ewing (1) · Thymus Neoplasms (1)
National Cancer Institute (NCI) (3)
United States (3)
David S Schrump, M.D. (2) · Brigitte C Widemann, M.D. (1)